Home » Topics » BioWorld Science, Cancer

BioWorld Science, Cancer
RSS

Disease stabilization in phase II multiple myeloma study of Panzem

Dec. 12, 2003

Vion enters research and option agreement for novel anticancer compounds

Dec. 12, 2003

Novel inhibitor of Stat3 activation with activity against hematological malignancies

Dec. 11, 2003

Antitumor efficacy of Bay-59-8862 in metastatic breast cancer

Dec. 11, 2003

Improved survival with RSR-13 plus WBRT in breast cancer patients with brain metastases

Dec. 11, 2003

Antitumor activity of E-7070 in metastatic breast cancer

Dec. 11, 2003

New phase II trials to evaluate KOS-862 for various cancers

Dec. 11, 2003

Sugen identifies potential surrogate markers for SU-11248 activity

Dec. 11, 2003

Dual-acting estrogen sulfatase inhibitor and SERM presented in San Antonio

Dec. 10, 2003

Avastin submitted for approval in Europe for colorectal cancer

Dec. 10, 2003

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 31, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 31, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...